FDA grants priority review to tarlatamab application to treat advanced small cell lung cancer
Amgen announced that the FDA has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for tarlatamab
Tarlatamab is a potential first-in-class, investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE ) therapy for the treatment of adult patients with advanced small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
"The FDA's Priority Review designation for this application underscores the urgency to provide new treatment options for patients with advanced SCLC who have progressed following treatment with platinum-based chemotherapy," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "While first-line treatments often show strong responses, patients can experience aggressive recurrences and long-term survival remains a challenge. Unfortunately, for patients who relapse, there are limited treatment options, emphasizing the importance of bringing new therapies to this patient population with advanced disease."
The FDA grants Priority Review to applications for medicines that offer, if approved, significant improvements over available options or may provide a treatment option where no adequate therapy currently exists. Based on the Priority Review designation, the Prescription Drug User Fee Action (PDUFA) date for tarlatamab is June 12, 2024.
The BLA is based on the Phase II results from the DeLLphi-301 clinical trial that studied patients with advanced SCLC with disease progression on or after platinum-based chemotherapy. Results from the study were recently featured as part of a late-breaking presentation during the 2023 European Society for Medical Oncology (ESMO) Congress and simultaneously published in the New England Journal of Medicine. The data presented demonstrated antitumor activity with a durable response and encouraging survival outcomes in previously treated SCLC. The safety profile was consistent with the Phase 1 trial.
See- "Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer".-Myung-Ju Ahn, M.D., Ph.D., Byoung Chul Cho, M.D., Ph.D., Enriqueta Felip, M.D., Ph.D., Ippokratis Korantzis, M.D., Kadoaki Ohashi, M.D., Ph.D.,et al.,for the DeLLphi-301 Investigators .November 30, 2023N Engl J Med 2023; 389:2063-2075 DOI: 10.1056/NEJMoa2307980.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.